Nippon Express Bangladesh Ltd. (hereinafter, "NE Bangladesh"), a local 
subsidiary of Nippon Express Co., Ltd. based in Tokyo, has obtained Good 
Distribution Practice (GDP) certification effective Sunday, December 13, 2020, 
evidencing its compliance with standards for the proper distribution of 
pharmaceuticals applicable to air cargo import/export services.

Logo: https://kyodonewsprwire.jp/img/202101250149-O2-yaMEw532

Photo: Exterior view of NE Bangladesh 
https://kyodonewsprwire.jp/prwfile/release/M103866/202101250149/_prw_PI1fl_h2wjD534.jpg


Bangladesh has a population of approximately 170 million and an annual gross 
domestic product (GDP) growth rate of 7%-8%, and the country is expected to see 
4.5% growth in 2020 and 2021 despite the coronavirus pandemic.

Bangladesh's pharmaceutical market is forecast to grow from its present scale 
of $3 billion to $6 billion by 2025, with this increase to be especially 
conspicuous in the already booming production of generic pharmaceuticals.

Having acquired GDP certification, NE Bangladesh will be better able to respond 
to expanding imports of active pharmaceutical ingredients from Europe and 
Japan, and exports of pharmaceuticals to destinations in Europe, the Middle 
East, Africa and elsewhere. The company will be collaborating with other Nippon 
Express Group companies that have already obtained GDP certification to extend 
its services globally. The company is also planning to add 
temperature-controlled trucks to its fleet in 2021.

Nippon Express will continue stepping up its efforts on behalf of the 
pharmaceutical industry and enhancing its services to meet increasingly 
sophisticated and diversified pharmaceutical needs.

-Profile of facility
Name: Nippon Express Bangladesh Ltd.
Address: 2nd Floor, Arzed Chamber,13, Mohakhali C/A, Dhaka-1212

Nippon Express website: http://www.nipponexpress.com/

Official LinkedIn Account: NIPPON EXPRESS GROUP
https://www.linkedin.com/company/nippon-express-group/


SOURCE: Nippon Express Co., Ltd.